Archives of Cardiovascular Diseases最新文献

{"title":"New onset atrial fibrillation in acute coronary syndrome: Prevalence, risk factors, and long-term outcomes in a Tunisian population","authors":"M. Ben Halima,&nbsp;Z. Jebbari,&nbsp;K. Ezzaouia,&nbsp;W. Yaakoubi,&nbsp;S. Ouali,&nbsp;F. Meghaieth,&nbsp;A. Farhati,&nbsp;R. Ben Rejeb,&nbsp;N. Larbi,&nbsp;S. Boudiche,&nbsp;M.S. Mourali","doi":"10.1016/j.acvd.2025.10.038","DOIUrl":"10.1016/j.acvd.2025.10.038","url":null,"abstract":"<div><h3>Introduction</h3><div>New-onset AF atrial fibrillation (NOAF) frequently complicates acute coronary syndromes (ACS) leading to adverse outcomes in the short and long term. The reported incidence ranges from 2 to 37% according to recent studies and a number of factors have consistently been shown to be associated with this arrhythmia.</div></div><div><h3>Objective</h3><div>The aim of the study was to determine the prevalence of NOAF in a population of patients admitted for ACS and to identify its predictive factors and study their prognosis.</div></div><div><h3>Method</h3><div>We carried out a prospective, descriptive and comparative observational study during a period of 10 months from January 2023 to November 2023 in the Cardiology department of the Rabta hospital. We included in our study consecutively hospitalized patients with acute coronary syndrome (ACS) who did not have a previous diagnosis of AF.</div></div><div><h3>Results</h3><div>In our study, we included 404 patients hospitalized for ACS. The prevalence of NOAF was 10%. In the multivariate analytical study, we found that age greater than 62 years (<em>P</em> <!-->=<!--> <!-->0.04; adjusted OR<!--> <!-->=<!--> <!-->4.83; CI95%: 1.07–21.77), chronic renal failure (<em>P</em> <!-->=<!--> <!-->0.043; adjusted OR<!--> <!-->=<!--> <!-->6.61; CI95%: 1.06–35.80), history of stroke (<em>P</em> <!-->=<!--> <!-->0.002; adjusted OR<!--> <!-->=<!--> <!-->44.51; CI95%: 3.97–498.10) and uricemia<!--> <!-->≥<!--> <!-->62<!--> <!-->mg/l (<em>P</em> <!-->=<!--> <!-->0.04; adjusted OR<!--> <!-->=<!--> <!-->4.4; CI95%: 1.06–18.15) were independent predictive factors of NOAF. NOAF was associated with a higher in-hospital mortality (5% vs. 0.5% in the group without AF; <em>P</em> <!-->=<!--> <!-->0.04) as well as a higher incidence of in-hospital major cardiovascular events (69% versus 24%; <em>P</em> <!-->=<!--> <!-->0.009). For the 183 patients followed over a mean period of 12 months, the NOAF was associated with a higher extra-hospital mortality (13% vs 6% in the group without AF; <em>P</em> <!-->=<!--> <!-->0.03) but there was not significant difference between patients with and without AF for major cardiovascular events.</div></div><div><h3>Conclusion</h3><div>The prevalence of NOAF in patients with ACS was 10%. Its systematic screening in these patients appears to be a relevant approach because of the strong association between the two pathologies in this population, and the pejorative impact on the prognosis of this arrythmia.</div></div>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"119 1","pages":"Page S23"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145904255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of gender and diabetes on the outcome of patients undergoing percutaneous coronary intervention with rotational atherectomy","authors":"P. Chenard,&nbsp;A.M. Boutaleb,&nbsp;V. Coussens,&nbsp;A. Cianci,&nbsp;L. Lebivic,&nbsp;V. Aboyans,&nbsp;M. Boukhris","doi":"10.1016/j.acvd.2025.10.040","DOIUrl":"10.1016/j.acvd.2025.10.040","url":null,"abstract":"<div><h3>Introduction</h3><div>The complexity of coronary lesions treated by percutaneous coronary intervention (PCI) has gradually increased with high prevalence of calcified lesions. The use of rotational atherectomy (RA) has become more common. However, the outcome of such a debulking device in specific patient subsets remains not well understood.</div></div><div><h3>Objective</h3><div>This study aimed to investigate the combined impact of gender and diabetes on the management and outcomes of patients undergoing PCI with RA.</div></div><div><h3>Method</h3><div>We conducted a retrospective single-center study of patients who underwent PCI with RA between January 2019 and December 2022. The primary outcome was the occurrence of major adverse cardiovascular events (MACE), including myocardial infarction (MI), cardiovascular (CV) death, and target vessel failure (TVF). Secondary outcomes included individual occurrences of MI, CV death, and TVF, along with data on technical success and safety outcomes, such as per-procedural and in-hospital complications.</div></div><div><h3>Results</h3><div>A total of 238 patients (mean age 77.2<!--> <!-->±<!--> <!-->9.2 years; 74.8% male; diabetes prevalence 36.1%) were included: men with diabetes (<em>n</em> <!-->=<!--> <!-->66, 27.7%), women with diabetes (<em>n</em> <!-->=<!--> <!-->20, 8.4%), men without diabetes (<em>n</em> <!-->=<!--> <!-->112, 47.1%), and women without diabetes (<em>n</em> <!-->=<!--> <!-->40, 16.8%).</div><div>No in-hospital death was observed in patients without diabetes. In presence of diabetes, in-hospital death was significantly higher in women as compared with men (7.5% vs. 0.9%; <em>P</em> <!-->=<!--> <!-->0.025).</div><div>The mean follow-up was 2.40<!--> <!-->±<!--> <!-->1.41 years. Men with diabetes had a higher incidence of MACE than men without diabetes (<em>P</em> <!-->=<!--> <!-->0.037) (<span><span>Fig. 1</span></span>), mainly due to more MI (<em>P</em> <!-->&lt;<!--> <!-->0.01). No significant difference was found in CV death (<em>P</em> <!-->=<!--> <!-->0.995) or TVF (<em>P</em> <!-->=<!--> <!-->0.285). After adjustment, diabetes was an independent predictor of MACE in men [hazard ratio (HR)<!--> <!-->=<!--> <!-->1.97; 95% CI: 1.04–3.71; <em>P</em> <!-->=<!--> <!-->0.037], but not in women.</div></div><div><h3>Conclusion</h3><div>In patients who underwent PCI with RA, women were more prone to have in-hospital complications, while long-term outcomes were worse in men, especially those with diabetes.</div></div>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"119 1","pages":"Page S24"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145904257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular health: Prevent, innovate, share","authors":"Pr Victor Aboyans (Scientific Secretary of JESFC),&nbsp;Pr Anne Bernard (Deputy Scientific Secretary, in charge of the Simulation Village),&nbsp;Pr Stéphane Lafitte (in charge of CME and the Digital Village),&nbsp;Pr Hélène Eltchaninoff (President-Elect of the SFC),&nbsp;Pr Christophe Leclercq (Past President of the SFC),&nbsp;Pr Bernard Iung (President of the SFC)","doi":"10.1016/j.acvd.2025.12.004","DOIUrl":"10.1016/j.acvd.2025.12.004","url":null,"abstract":"","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"119 1","pages":"Pages S1-S2"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145904075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of right ventricular dysfunction on transcatheter mitral valve implantation outcomes, and subsequent evolution of right ventricular function","authors":"Audrey Cailliau ,&nbsp;Caroline Nguyen ,&nbsp;Eric Brochet ,&nbsp;John Kikoine ,&nbsp;Clemence Delhomme ,&nbsp;Gaspard Suc ,&nbsp;Bernard Iung ,&nbsp;Dominique Himbert ,&nbsp;Marina Urena","doi":"10.1016/j.acvd.2026.01.002","DOIUrl":"10.1016/j.acvd.2026.01.002","url":null,"abstract":"<div><h3>Background</h3><div>The impact of right ventricular dysfunction on transcatheter mitral valve implantation outcomes and the evolution of right ventricular function after the procedure has not been described.</div></div><div><h3>Aims</h3><div>To analyse the impact of right ventricular dysfunction on immediate and mid-term outcomes of transcatheter mitral valve implantation, and the evolution of right ventricular function in these patients.</div></div><div><h3>Methods</h3><div>Consecutive patients who underwent transcatheter mitral valve implantation in our institution were included. Right ventricular function was assessed before transcatheter mitral valve implantation by transthoracic echocardiography, using a multivariable approach. Patients were divided into two groups according to the preprocedural presence of right ventricular dysfunction. Patients were followed up at 3 months and 1 year with a new echocardiographic assessment at each time point.</div></div><div><h3>Results</h3><div>Among 109 patients finally included (mean age 65<!--> <!-->±<!--> <!-->19 years; 66% women), 77 (71%) had normal right ventricular function and 32 (29%) had right ventricular dysfunction before transcatheter mitral valve implantation. Technical success was achieved in 92 (84%) patients. At 30 days, there were no differences between the group with normal right ventricular function and the group with right ventricular dysfunction in terms of death (5 vs. 6%; <em>P</em> <!-->=<!--> <!-->0.86), all-cause rehospitalization (20 vs. 31%; <em>P</em> <!-->=<!--> <!-->0.17) and heart failure without hospitalization (13 vs. 6%; <em>P</em> <!-->=<!--> <!-->0.5). Although the 1-year survival rate was higher in the group with normal right ventricular function (83.1%, 95% confidence interval 74.3% to 92.9%) than in the group with right ventricular dysfunction (68.2%, 95% confidence interval 52.9% to 88.1%) (<em>P</em> <!-->=<!--> <!-->0.09), these differences were not significant after adjustment. Transcatheter mitral valve implantation was associated with improved right ventricular function in the group with initial right ventricular dysfunction at 1-year follow-up (<em>P</em> <!-->&lt;<!--> <!-->0.01).</div></div><div><h3>Conclusions</h3><div>Right ventricular dysfunction does not appear to have an impact on the early outcomes of transcatheter mitral valve implantation. However, it was associated with an increased rate of late death, although differences were not statistically significant after adjustment. Successful transcatheter mitral valve implantation in patients with severe mitral valve disease associated with right ventricular dysfunction leads to significant improvement in right ventricular function.</div></div>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"119 1","pages":"Pages 63-71"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146133580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of the HELIOS-B monotherapy population: A post hoc analysis censoring data following tafamidis initiation","authors":"R. Witteles ,&nbsp;A. Kristen ,&nbsp;G. Habib ,&nbsp;O. Azevedo ,&nbsp;D. Rodriguez-Duque ,&nbsp;E. Aldinc ,&nbsp;S. Eraly ,&nbsp;J. González-Costello","doi":"10.1016/j.acvd.2025.10.069","DOIUrl":"10.1016/j.acvd.2025.10.069","url":null,"abstract":"<div><h3>Introduction</h3><div>In HELIOS-B, vutrisiran significantly reduced the risk of the primary endpoint composite of all-cause mortality (ACM) and recurrent cardiovascular (CV) events, and met all secondary endpoints (including ACM at 42 months), vs placebo in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) in both the overall and monotherapy (patients not receiving tafamidis at baseline) populations. In the monotherapy population, 21.5% of patients initiated tafamidis after randomization during the double-blind period.</div></div><div><h3>Objective</h3><div>To evaluate the efficacy of vutrisiran versus placebo in the monotherapy population of HELIOS-B.</div></div><div><h3>Method</h3><div>Patients were randomized 1:1 to receive vutrisiran 25<!--> <!-->mg or placebo every 12 weeks for up to 36 months. Patients who were not receiving tafamidis at baseline (monotherapy population) could initiate tafamidis after enrollment depending on the investigator's decision and the availability of tafamidis. This analysis censored patient observations in the monotherapy population post-tafamidis initiation, and then repeated the primary analyses of the HELIOS-B study.</div></div><div><h3>Results</h3><div>A total of 395 patients in HELIOS-B were in the vutrisiran monotherapy population and were included in this analysis. Of these, 85 (21.5%) initiated tafamidis post randomization (vutrisiran <em>n</em> <!-->=<!--> <!-->44; placebo <em>n</em> <!-->=<!--> <!-->41) during the double-blind period. The results from this post hoc analysis are consistent with the results of the original primary analysis of the monotherapy population, and demonstrate the efficacy of vutrisiran vs placebo, when observations post-tafamidis initiation were censored. The hazard ratios for vutrisiran vs placebo were 0.67 and 0.71 for the composite primary endpoint of ACM and recurrent CV events and 0.66 and 0.67 for the secondary endpoint of ACM before and after censoring, respectively. The results were also consistent for other secondary endpoints (<span><span>Table 1</span></span>).</div></div><div><h3>Conclusion</h3><div>The efficacy of vutrisiran vs placebo is consistent after the observations following tafamidis initiation in the monotherapy population of HELIOS-B were censored. This provides further evidence supporting the efficacy of vutrisiran as monotherapy in patients with ATTR-CM.</div></div>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"119 1","pages":"Pages S38-S39"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145903980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Characteristics of Heart Failure Patients According to QRS Morphology","authors":"F. Yahia ,&nbsp;F. Mansour ,&nbsp;N. Elyes ,&nbsp;E. Allouche ,&nbsp;S. Ouali","doi":"10.1016/j.acvd.2025.10.085","DOIUrl":"10.1016/j.acvd.2025.10.085","url":null,"abstract":"<div><h3>Introduction</h3><div>QRS morphology reflects underlying conduction system abnormalities and myocardial disease, potentially influencing prognosis in heart failure (HF) patients.</div></div><div><h3>Objective</h3><div>To compare clinical, echocardiographic, and therapeutic profiles of HF patients stratified by QRS morphology: left bundle branch block (LBBB), right bundle branch block (RBBB), intra-ventricular conduction delay (IVCD), left anterior fascicular block (LAFB), and narrow QRS complexes.</div></div><div><h3>Method</h3><div>A retrospective study of HF patients with LVEF<!--> <!-->&lt;<!--> <!-->50% was conducted and baseline characteristics, therapies, and echocardiographic data were analyzed.</div></div><div><h3>Results</h3><div>Patients with LBBB (24%) showed more severe left ventricular dilation (mean DTD<!--> <!-->=<!--> <!-->65.7<!--> <!-->mm, <em>P</em> <!-->=<!--> <!-->0.018) and depressed LVEF (mean 29.5%, <em>P</em> <!-->=<!--> <!-->0.047) (<span><span>Table 1</span></span>). RBBB patients (7.5%) exhibited higher prevalence of right ventricular dysfunction and signs of systemic congestion. IVCD patients displayed intermediate clinical and echocardiographic profiles between LBBB and RBBB. LAFB (10.5%) was associated with higher coronary artery disease prevalence (<em>P</em> <!-->=<!--> <!-->0.029) but milder clinical presentation. Narrow QRS patients (43.5%) had better preserved ventricular function and fewer signs of congestion. Therapeutic strategies, including device therapies, varied significantly across groups, notably a higher rate of CRT in LBBB patients.</div></div><div><h3>Conclusion</h3><div>QRS morphology is a powerful indicator of clinical and echocardiographic heterogeneity among HF patients. Recognition of specific conduction patterns can guide tailored management and improve risk stratification in HF with reduced or mid-range LVEF.</div></div>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"119 1","pages":"Pages S48-S49"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145904060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex-based differences in heart failure management and outcomes: Insights from the French-DataHF cohort","authors":"B. Baudry ,&nbsp;O. Pereira ,&nbsp;F. Roubille ,&nbsp;M. Villaceque ,&nbsp;T. Damy ,&nbsp;D. Kévin ,&nbsp;P. Tangre ,&nbsp;N. Girerd","doi":"10.1016/j.acvd.2025.10.075","DOIUrl":"10.1016/j.acvd.2025.10.075","url":null,"abstract":"<div><h3>Introduction</h3><div>Heart failure (HF) prognosis is influenced by demographic, clinical, and healthcare-related factors, with sex playing a crucial role. However, sex-based differences in HF management and outcomes remain insufficiently characterized in real-world settings.</div></div><div><h3>Objective</h3><div>This study aimed to assess sex-related disparities in HF prognosis and management using a comprehensive nationwide cohort.</div></div><div><h3>Method</h3><div>This study utilized the French-DataHF cohort, including all French patients diagnosed with HF in the previous five years and alive on January 1st, 2020. Inverse probability weighting (IPW) was applied to adjust for baseline differences in assessing prognosis and management. The primary outcome was all-cause mortality (ACM), while secondary outcomes included HF hospitalization and their composite. Survival analyses were performed using Cox proportional hazards models, adjusted for demographic, clinical, and healthcare factors.</div></div><div><h3>Results</h3><div>The study included 655,919 patients (48% female). One-year ACM was 16.8% in females vs. 15.1% in males. In IPW-adjusted analyses, females received less renin-angiotensin system inhibitors (52.8% vs. 61.5%), while a higher proportion had no annual cardiology follow-up (33.8% vs. 27.9%). In the fully adjusted model, females had a 21% lower ACM risk (aHR<!--> <!-->=<!--> <!-->0.79, 95% CI: 0.79–0.80) and a 15% lower composite outcome risk (aHR<!--> <!-->=<!--> <!-->0.85, 95% CI: 0.85–0.86). The benefits of cardiology follow-up were consistent across sexes, with a reduced ACM risk ranging from 21% for one consultation to 41% for ≥4 consultations.</div></div><div><h3>Conclusion</h3><div>While females had a better-adjusted prognosis, disparities in GDMT utilization and cardiology follow-up nonetheless persist. Enhancing access to specialized care for women with HF could further optimize outcomes and reduce mortality.</div></div>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"119 1","pages":"Page S43"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145904085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimal cut-off point of artificial intelligence-based global circumferential strain measured at stress for prediction of cardiovascular events","authors":"P.-J. Martial ,&nbsp;A. Eid ,&nbsp;S. Duhamel ,&nbsp;S. Toupin ,&nbsp;M. Akodad ,&nbsp;A. Neylon ,&nbsp;P. Garot ,&nbsp;T. Hovasse ,&nbsp;S. Champagne ,&nbsp;T. Chitiboi ,&nbsp;P. Sharma ,&nbsp;T. Gonçalves ,&nbsp;A. Unger ,&nbsp;J. Florence ,&nbsp;E. Gall ,&nbsp;J.-G. Dillinger ,&nbsp;P. Henry ,&nbsp;F. Sanguineti ,&nbsp;J. Garot ,&nbsp;T. Pezel","doi":"10.1016/j.acvd.2025.10.101","DOIUrl":"10.1016/j.acvd.2025.10.101","url":null,"abstract":"<div><h3>Introduction</h3><div>Although global circumferential strain (stress-GCS) measured during vasodilator stress cardiovascular magnetic resonance (CMR) has incremental prognostic value for prediction of major adverse cardiovascular events (MACE) above traditional stress CMR factors, no study has investigated the optimal cut-off of stress-GCS for MACE.</div></div><div><h3>Objective</h3><div>To determine the optimal cut-off point of stress-GCS for predicting MACE in a consecutive cohort of patients with normal stress CMR.</div></div><div><h3>Method</h3><div>Between 2017 and 2018, all consecutive patients with normal stress CMR defined by the absence of inducible ischemia and late gadolinium enhancement (LGE) were recruited retrospectively. Stress-GCS was measured using a fully automated machine-learning algorithm based on featured-tracking imaging from short-axis cine images. The primary composite outcome was MACE defined by cardiovascular death or nonfatal myocardial infarction. The survival tree method was used to identify the optimal cut-off for stress-GCS.</div></div><div><h3>Results</h3><div>In 1,321 patients (65<!--> <!-->±<!--> <!-->12 years, 67% men), 52 (3.9%) experienced a MACE after a median follow-up of 5.1 (4.8–5.4) years. The best cut-off of stress-GCS to predict MACE was −10%. After adjustment for traditional risk factors and stress CMR findings (LVEF), stress-GCS<!--> <!-->≥<!--> <!-->−10% was independently associated with MACE (adjusted HR, 12.4 [95% CI, 5.89–26.1], <em>p</em> <!-->&lt;<!--> <!-->0.001, <span><span>Fig. 1A</span></span>). The annualized rate of MACE in patients with stress-GCS<!--> <!-->≥<!--> <!-->–10% was significantly higher than patients with stress-GCS<!--> <!-->&lt;<!--> <!-->−10% (<span><span>Fig. 1B</span></span>). An increased stress-GCS<!--> <!-->≥<!--> <!-->−10% showed the best improvement in model discrimination and reclassification above traditional and stress CMR findings (C-statistic improvement: 0.14; NRI<!--> <!-->=<!--> <!-->0.430; IDI<!--> <!-->=<!--> <!-->0.089, all <em>p</em> <!-->&lt;<!--> <!-->0.001; LR-test <em>p</em> <!-->&lt;<!--> <!-->0.001).</div></div><div><h3>Conclusion</h3><div>Using the optimal cut-off of stress-GCS, a stress-GCS value<!--> <!-->≥<!--> <!-->−10% is independently associated with MACE in patients with normal stress CMR, with an incremental prognostic value over traditional risk factors and stress CMR findings.</div></div>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"119 1","pages":"Page S59"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145904215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determinants of hospital mortality and echocardiographic extent of cardiomyopathy in congestive heart failure patients: A multicenter cross-sectional study in Kinshasa","authors":"M. Tshilanda Balekelayi,&nbsp;M. Brady,&nbsp;L.N. Yves,&nbsp;S.M. Yannick,&nbsp;B.B. Nathan","doi":"10.1016/j.acvd.2025.10.091","DOIUrl":"10.1016/j.acvd.2025.10.091","url":null,"abstract":"<div><h3>Introduction</h3><div>Heart failure (HF) is caused by various lesions of the heart. Cardiomyopathies are one of the major causes of HF along with ischemic heart disease and hypertensive heart disease.</div></div><div><h3>Objective</h3><div>To identify the determinants of hospital mortality in patients with congestive heart failure (CHF) in the city of Kinshasa.</div></div><div><h3>Method</h3><div>This is a multicenter analytical cross-sectional study based on non-probability convenience sampling for the selection of 454 cases of congestive heart failure hospitalized in three hospitals in the city of Kinshasa in the Democratic Republic of Congo (DRC) from June 2021 to June 2024. The data collected were analyzed with Stata/IC version 15 software. The variables were presented in the form of central tendencies and frequencies. The determinants were identified using logistic regression.</div></div><div><h3>Results</h3><div>281 women and 173 men were evaluated, with a sex ratio M/F of 0.6 with a median age of 63 years. High blood pressure (HBP) was the most common cardiovascular risk factor (68.5%). Respiratory infections were the most common contributing factor (38.7%). HF-related mortality was 22.5%. Cardiomyopathies were the most common cause of HF with 239 cases or 52.6%. The mean left ventricular ejection fraction (LVEF) of our population was 39.6<!--> <!-->±<!--> <!-->10.5%.</div><div>Systolic blood pressure greater than or equal to 90<!--> <!-->mmHg emerged as a protective factor against HF-related mortality (ORa<!--> <!-->=<!--> <!-->0.05; <em>P</em> <!-->&lt;<!--> <!-->0.001) with sinus rhythm (ORa<!--> <!-->=<!--> <!-->0.5; <em>P</em> <!-->=<!--> <!-->0.042), glomerular filtration rate (GFR) greater than or equal to 30<!--> <!-->ml/min (ORa<!--> <!-->=<!--> <!-->0.2; <em>P</em> <!-->&lt;<!--> <!-->0.001) and normal serum potassium (ORa<!--> <!-->=<!--> <!-->0.5; <em>P</em> <!-->=<!--> <!-->0.008) (<span><span>Table 1</span></span>).</div></div><div><h3>Conclusion</h3><div>Cardiomyopathies represent the most frequent cause of HF in our environment and require in-depth knowledge of their mechanisms of occurrence in order to establish solid means for their eradication.</div></div>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"119 1","pages":"Pages S51-S52"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145904217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Redo versus first transcatheter aortic valve implantation: A propensity score-matched analysis","authors":"Pierre Deharo ,&nbsp;Ferdinando Sabatino ,&nbsp;Christophe Saint Etienne ,&nbsp;Jeremy Boyer ,&nbsp;Anne Bernard ,&nbsp;Thierry Bourguignon ,&nbsp;Carl Semaan ,&nbsp;Jean Michel Clerc ,&nbsp;Thomas Cuisset ,&nbsp;Laurent Fauchier","doi":"10.1016/j.acvd.2025.11.002","DOIUrl":"10.1016/j.acvd.2025.11.002","url":null,"abstract":"<div><h3>Background</h3><div>Redo transcatheter aortic valve implantation (TAVI) is increasingly used to treat bioprosthetic valve dysfunction in patients who have undergone TAVI. As TAVI indications continue to expand to include younger patients, it is essential to systematically document redo TAVI procedures to better understand their long-term efficacy and safety. This study aimed to compare outcomes between redo TAVI and first TAVI procedures using a propensity score-matched analysis.</div></div><div><h3>Aims</h3><div>To compare the long-term clinical outcomes, including death, stroke and procedural adverse events, between redo TAVI and first TAVI procedures using a propensity score-matched analysis.</div></div><div><h3>Methods</h3><div>A retrospective analysis was conducted using the TriNetX database, identifying adults (≥<!--> <!-->18<!--> <!-->years) with severe aortic stenosis who underwent TAVI (2012–2024). Redo TAVI required an interval of ≥<!--> <!-->12<!--> <!-->months. Propensity score matching was performed using all baseline characteristics listed in Table 1, with outcomes assessed over 36<!--> <!-->months.</div></div><div><h3>Results</h3><div>After matching, 446 patients were included in each cohort. No statistically significant difference was observed in the annual rates of all-cause death (11.3% vs 8.7%; hazard ratio 1.20, 95% confidence interval 0.86–1.68), ischaemic stroke (hazard ratio 2.07, 95% confidence interval 0.99–4.35) or major bleeding (hazard ratio 1.41, 95% confidence interval 0.99–2.02) between the redo TAVI and first TAVI groups. Pacemaker implantation (hazard ratio 0.25, 95% confidence interval 0.12–0.51), new-onset atrial fibrillation (hazard ratio 0.44, 95% confidence interval 0.24–0.79) and hospitalization for heart failure (hazard ratio 0.64, 95% confidence interval 0.41–0.99) were significantly lower in the redo TAVI group.</div></div><div><h3>Conclusions</h3><div>No statistically significant difference was observed in all-cause death, ischaemic stroke or major bleeding between the redo TAVI and first TAVI groups. Conversely, redo TAVI was associated with significantly lower rates of permanent pacemaker implantation and heart failure rehospitalization. These findings support the integration of redo TAVI as an essential component within a comprehensive lifetime treatment strategy for managing bioprosthetic aortic valve dysfunction.</div></div>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"119 1","pages":"Pages 25-31"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146193176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}